Evotec Results Presentation Deck

PAGE 21 evotec New manufacturing options to avoid biologics shortage in EU Campus Curie home for new J.POD® showcases next-generation options Europe is second-largest market for biologics; local capacities to secure supply urgently needed • J.POD® 2 EU creates operational efficiency and capacity for biological treatments in EU ● Strong support from French government, Occitanie region, Bpifrance, Haute-Garonne prefecture as well as Toulouse Métropole ● Two hectares of land¹) at Campus Curie already identified and design plan started Opportunity to build global J.PODⓇ network ¹) Dependent of local plannings, environmental and building requirements as well as further conditions evotec NEWS RELEASE, 20 APRIL 2021 #RESEARCHNEVERSTOPS EVOTEC ACCELERATES ACCESS TO BIOLOGIC THERAPEUTICS WITH INITIATION OF MANUFACTURING FACILITY IN TOULOUSE ► J.POD 2 EU BIOMANUFACTURING WILL PLAY A KEY ROLE IN ADDRESSING THE NEED FOR THERAPEUTIC ANTIBODIES, INCLUDING THOSE RELATED TO INFECTIOUS DISEASES SUCH AS COVID-19 ▸ EVOTEC WILL BE SUPPORTED BY THE FRENCH GOVERNMENT AS WELL AS THE OCCITANIE REGION, BPIFRANCE, THE HAUTE-GARONNE PREFECTURE AND TOULOUSE MÉTROPOLE CONSTRUCTION OF THE J.POD 2 EU FACILITY TO START IN H2 2021 Hamburg, Germany, 20 April 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France. J.POD 2 EU, Evotec's second innovative cGMP biomanufacturing facility, will employ Just - Evotec Biologics' cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms. J.POD® 2 EU will be Evotec's first commercial biomanufacturing facility in Europe and is anticipated to deliver much needed capacity, flexibility and quality for biotherapeutic development and manufacturing. The construction of Evotec's first J.POD® 1 US in Redmond, Washington is proceeding on schedule and will be fully operational in H2 2021. With its wholly owned subsidiary, Just - Evotec Biologics, Evotec is ideally positioned to build the capacity required for the fight against COVID-19 and future pandemic threats delivering rapid, high quality outcomes. Evotec is supporting multiple projects against COVID-19, including partnerships with the Bill & Melinda Gates Foundation and the United States Department of Defense. In addition to J.POD technology, Evotec is building unparalleled data-driven scientific capabilities to meet future viral threats, which include fast discovery, optimisation and development of novel therapeutic agents. For further information, please contact: Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing. [email protected], T. +49(0)40.560 81-255, F. +49(0)40.560 81-333, www.evotec.com

View entire presentation